RNA THERAPEUTICS

Leading the next generation of digital molecule design with explainable AI

We uncover the most important factors that predict the drug properties you want.

PRODUCTS + SERVICES >

TESTIMONIALS >

CASE STUDIES >

Rapidly design better RNA therapeutics

Our proprietary, explainable AI, combined with our expertise in RNA therapeutics, bioinformatics, and machine learning, gives you the explainable edge in RNA therapeutic design.

Flexibility to suit your needs

Augment your team with Abzu.

Licensed access, custom designed oligos, or partnership from initial tile design through lead optimisation.

Scientific understanding of drug properties of RNA therapeutics

Enhanced library design

Custom library of digital molecules for lead generation and optimization.

Abzu logo - XAI for RNATx

xAI modeling

Iterative lead optimization with our proprietary xAI and our experts in RNA therapeutics.

Potential deliverable: A report withg findings about RNATx efficacy, toxicity, etc

Digital report

Progress, recommendations, and actions to develop safe and efficacious therapeutics.

LET'S TALK >
Scientific ideas

Why Abzu?

We use our expertise in bioinformatics, data science, and RNA therapeutics, together with our xAI framework, to deliver novel insights to digitally design better molecules.

WHY ABZU >

LET’S GET STARTED >

What people are saying

Although Abzu's QLattice (and its collaborative scientists) have helped improve the performance of our drug design algorithms, it's the explainability of the QLattice models that is — in our setting — the most valuable feature for us.
Morten Lindow
Morten LindowMatrix Lead, Therapeutic Modalities @ Roche
Hypotheses generated by Abzu's explainable AI QLattice technology are brilliantly put into context with our knowledge graphs. I believe a combined setup like ours is a very realistic picture of the future of data science.
Umut Eser
Umut EserChief Innovation Officer @ Dr.Evidence
While we consider ourselves world-leading in the computational design of oligonucleotide-based therapies, our collaboration with Abzu has added new aspects when applying machine learning to drug discovery data.
Morten Lindow
Morten LindowMatrix Lead, Therapeutic Modalities @ Roche
Abzu's QLattice helps determine the precise genomic locations for controlling transcription factor binding and modulating gene expression of a given target. This is a major step forward for genomic medicines.
Thomas Tibbitts
Thomas TibbittsCEO + Founder @ Dogodan Therapeutics
Abzu’s explainable artificial intelligence technology and in-house RNA and data science capabilities, combined with their service-based business model, is a key stepping stone executing our R&D strategy.
Kenneth Vielsted Christensen
Kenneth Vielsted ChristensenCSO @ Contera Pharma

Abzu recognized as a Cool Vendor in artificial intelligence

Abzu is named a “Cool Vendor” in the 2022 Gartner® “AI Governance and Responsible AI — From Principles to Practice” report.

READ MORE >

READ THE REPORT >

Abzu is a Gartner Cool Vendor 2022

Read more

Contact Abzu

We’re just a bunch of nice nerds building something new and awesome. How can we help you?

Disclaimer

Gartner® and Cool Vendors™ are registered trademarks and service marks, and the Gartner Cool Vendor badge is a trademark and service mark of Gartner, Inc. and/or its affiliates, and are used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

Read the 2022 Gartner® Cool Vendors™ in AI Governance and Responsible AI — From Principles to Practice report.